Novel method synthesizes Retatrutide in a flexible way, suggesting improvement over traditional techniques.
Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). At present, its synthesis relies predominantly on solid-phase peptide synthesis (SPPS), an approach that suffers from inherent limitations in terms of efficiency, scalability, and structural flexibility. In this study, we present a novel method for the synthesis of Retatrutide, namely hydrophobic tag-assisted liquid-phase peptide synthesis (LPPS). This method provides a practical and flexible alternative to conventional SPPS for the synthesis of Retatrutide.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: